229 related articles for article (PubMed ID: 24009313)
1. Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophy.
Van Ry PM; Minogue P; Hodges BL; Burkin DJ
Hum Mol Genet; 2014 Jan; 23(2):383-96. PubMed ID: 24009313
[TBL] [Abstract][Full Text] [Related]
2. Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy.
Rooney JE; Knapp JR; Hodges BL; Wuebbles RD; Burkin DJ
Am J Pathol; 2012 Apr; 180(4):1593-602. PubMed ID: 22322301
[TBL] [Abstract][Full Text] [Related]
3. Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A.
Doe JA; Wuebbles RD; Allred ET; Rooney JE; Elorza M; Burkin DJ
J Cell Sci; 2011 Jul; 124(Pt 13):2287-97. PubMed ID: 21652631
[TBL] [Abstract][Full Text] [Related]
4. Autophagy is increased in laminin α2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A.
Carmignac V; Svensson M; Körner Z; Elowsson L; Matsumura C; Gawlik KI; Allamand V; Durbeej M
Hum Mol Genet; 2011 Dec; 20(24):4891-902. PubMed ID: 21920942
[TBL] [Abstract][Full Text] [Related]
5. Impaired fetal muscle development and JAK-STAT activation mark disease onset and progression in a mouse model for merosin-deficient congenital muscular dystrophy.
Nunes AM; Wuebbles RD; Sarathy A; Fontelonga TM; Deries M; Burkin DJ; Thorsteinsdóttir S
Hum Mol Genet; 2017 Jun; 26(11):2018-2033. PubMed ID: 28334989
[TBL] [Abstract][Full Text] [Related]
6. Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy.
Hara Y; Mizobe Y; Miyatake S; Takizawa H; Nagata T; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():553-564. PubMed ID: 30171567
[TBL] [Abstract][Full Text] [Related]
7. Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A.
Kumar A; Yamauchi J; Girgenrath T; Girgenrath M
Hum Mol Genet; 2011 Jun; 20(12):2333-43. PubMed ID: 21441569
[TBL] [Abstract][Full Text] [Related]
8. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice.
Aoki Y; Nagata T; Yokota T; Nakamura A; Wood MJ; Partridge T; Takeda S
Hum Mol Genet; 2013 Dec; 22(24):4914-28. PubMed ID: 23882132
[TBL] [Abstract][Full Text] [Related]
9. Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.
Gawlik KI; Holmberg J; Svensson M; Einerborg M; Oliveira BM; Deierborg T; Durbeej M
Sci Rep; 2017 Mar; 7():44059. PubMed ID: 28281577
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice.
Bentzinger CF; Barzaghi P; Lin S; Ruegg MA
FASEB J; 2005 Jun; 19(8):934-42. PubMed ID: 15923403
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition improves the muscle of laminin α2 chain-deficient mice.
Carmignac V; Quéré R; Durbeej M
Hum Mol Genet; 2011 Feb; 20(3):541-52. PubMed ID: 21084425
[TBL] [Abstract][Full Text] [Related]
12. Distribution of ten laminin chains in dystrophic and regenerating muscles.
Patton BL; Connoll AM; Martin PT; Cunningham JM; Mehta S; Pestronk A; Miner JH; Sanes JR
Neuromuscul Disord; 1999 Oct; 9(6-7):423-33. PubMed ID: 10545049
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.
Xu R; Chandrasekharan K; Yoon JH; Camboni M; Martin PT
Am J Pathol; 2007 Jul; 171(1):181-99. PubMed ID: 17591965
[TBL] [Abstract][Full Text] [Related]
14. Secondary reduction of alpha7B integrin in laminin alpha2 deficient congenital muscular dystrophy supports an additional transmembrane link in skeletal muscle.
Cohn RD; Mayer U; Saher G; Herrmann R; van der Flier A; Sonnenberg A; Sorokin L; Voit T
J Neurol Sci; 1999 Mar; 163(2):140-52. PubMed ID: 10371075
[TBL] [Abstract][Full Text] [Related]
15. Laminin-α2 Chain-Deficient Congenital Muscular Dystrophy: Pathophysiology and Development of Treatment.
Durbeej M
Curr Top Membr; 2015; 76():31-60. PubMed ID: 26610911
[TBL] [Abstract][Full Text] [Related]
16. Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A.
Yamauchi J; Kumar A; Duarte L; Mehuron T; Girgenrath M
Hum Mol Genet; 2013 Nov; 22(21):4306-17. PubMed ID: 23773998
[TBL] [Abstract][Full Text] [Related]
17. Integrins (alpha7beta1) in muscle function and survival. Disrupted expression in merosin-deficient congenital muscular dystrophy.
Vachon PH; Xu H; Liu L; Loechel F; Hayashi Y; Arahata K; Reed JC; Wewer UM; Engvall E
J Clin Invest; 1997 Oct; 100(7):1870-81. PubMed ID: 9312189
[TBL] [Abstract][Full Text] [Related]
18. Mesoangioblast delivery of miniagrin ameliorates murine model of merosin-deficient congenital muscular dystrophy type 1A.
Domi T; Porrello E; Velardo D; Capotondo A; Biffi A; Tonlorenzi R; Amadio S; Ambrosi A; Miyagoe-Suzuki Y; Takeda S; Ruegg MA; Previtali SC
Skelet Muscle; 2015; 5():30. PubMed ID: 26347253
[TBL] [Abstract][Full Text] [Related]
19. Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies.
Gawlik KI; Durbeej M
Skelet Muscle; 2011 Mar; 1(1):9. PubMed ID: 21798088
[TBL] [Abstract][Full Text] [Related]
20. Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice.
Guo LT; Zhang XU; Kuang W; Xu H; Liu LA; Vilquin JT; Miyagoe-Suzuki Y; Takeda S; Ruegg MA; Wewer UM; Engvall E
Neuromuscul Disord; 2003 Mar; 13(3):207-15. PubMed ID: 12609502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
